Type 1 diabetes is at best a huge nuisance and at worst a constant threat of death for up to 3 million Americans whose pancreases don’t produce insulin. Technology has improved the life of some diabetics, with insulin pumps replacing manual injections and glucose monitors that keep constant watch of diabetics’ blood-sugar levels, reducing the need for finger-pricks. Yet diabetics are still required to frequently monitor and adjust their insulin levels.
Now one company, Animas Corp., has completed the first successful human trial of a made-for-market artificial pancreas that takes care of everything automatically.
